Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.50 |
| ▸ | TYR | P14679 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8346737 | 0.82 | KDM4E (0.57) | DAOTYRKDM4EIDH1ALDH1A1 | |
| SCHEMBL19331445 | 0.82 | TYR (0.56) | DAOTYRKDM4EIDH1 | |
| Bromide SCHEMBL4417981 | 0.81 | KDM4E (0.56) | DAOTYRKDM4EIDH1ALDH1A1 | |
| SCHEMBL4160504 | 0.81 | TYR (0.54) | DAOTYRKDM4EIDH1 | |
| SCHEMBL14080538 | 0.79 | LDHA (0.41) | KDM4ELDHAL3MBTL1ALDH1A1 | |
| SCHEMBL20300185 | 0.70 | PKM (0.52) | DAOTYRKDM4EIDH1ALDH1A1 | |
| SCHEMBL14055930 | 0.70 | KDM4E (0.65) | KDM4EALDH1A1 | |
| SCHEMBL6167580 | 0.70 | DAO (0.66) | DAOTYRKDM4EIDH1 | |
| Kojic Acid SCHEMBL5011817 | 0.69 | TYR (1.00) | DAOTYRKDM4EIDH1 | |
| Kojic Acid SCHEMBL9541984 | 0.68 | TYR (0.81) | DAOTYRKDM4EIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-7514432-B2 | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2009-04-07 | — | — | US | disclosed |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2006-08-17 | — | — | US | disclosed |
| EP-1597253-B1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2006-08-09 | — | — | EP | disclosed |
| EP-1597253-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | Exonhit Therapeutics S.A. (FR) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004076445-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | RB1, ALDH1A2, CDK4 | DAO 4494/4885TYR 421/4885KDM4E 2345/4885 |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | RB1, ALDH1A2, CDK4 | DAO 4494/4885TYR 421/4885KDM4E 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.